RxDoctor Payments Data

Hannah Miller, PA

Physician Assistant · Pittsburgh, PANPI 1093461444

Payments from drug & device makers

$3,175in general payments, 2019–2025

Across 135 payments — averaging $23.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$769
  • Novartis$499
  • Amgen$337
  • Pfizer$332
  • Boehringer Ingelheim$210
  • Cochlear Americas$140
  • plus $889 from 13 others

What the payments were for

  • Food & beverage$3,10398%
  • Education$722%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,175 in reported general payments places this provider in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$2,978
Medicare patients
23
Services billed
30

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban76$67,577
JardianceEmpagliflozin57$51,912
EntrestoSacubitril/Valsartan21$23,088
XareltoRivaroxaban24$23,019
BrilintaTicagrelor16$10,629
Repatha PushtronexEvolocumab12$7,481
Ranolazine ErRanolazine22$1,964
Metoprolol Succinate112$1,067
Valsartan33$624
Atorvastatin Calcium78$527
Bumetanide17$454
Amlodipine Besylate79$375
ClopidogrelClopidogrel Bisulfate62$354
Isosorbide Mononitrate ErIsosorbide Mononitrate28$332
Flecainide Acetate13$328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$332$67,57776 claims
Boehringer IngelheimJardiance$210$51,91257 claims
NovartisEntresto$499$23,08821 claims
Johnson & JohnsonXarelto$20$23,01924 claims
AstraZenecaBrilinta$101$10,62916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →